Tanespimycin坦螺旋霉素,75747-14-7

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Tanespimycin

CAS No. : 75747-14-7

MCE 国际站：Tanespimycin

产品活性：Tanespimycin (17-AAG) 是有效的 HSP90 抑制剂，IC₅₀ 为 5 nM，对肿瘤细胞 HSP90 的亲和性比正常细胞高 100 倍。Tanespimycin 消耗细胞内 STK38/NDR1，并降低 STK38 激酶活性。Tanespimycin 还下调 stk38 基因表达。

研究领域：Cell Cycle/DNA Damage  |  Metabolic Enzyme/Protease  |  Autophagy  |  Anti-infection  |  Apoptosis

作用靶点：HSP  |  Autophagy  |  Mitophagy  |  Bacterial  |  Apoptosis  |  Antibiotic

In Vitro: Tanespimycin causes the degradation of HER2, Akt, and both mutant and wild-type AR and the retinoblastoma-dependent G1 growth arrest of prostate cancer cells. Tanespimycin inhibits prostate cancer cell lines with IC₅₀s ranged from 25-45 nM (LNCaP, 25 nM; LAPC-4, 40 nM; DU-145, 45 nM; and PC-3, 25 nM).
Tanespimycin (0.1-1 μM) induces a nearly complete loss of ErbB2 on ErbB2-overexpressing breast cancer cells. Tanespimycin inhibits cell growth and induces G2/M cell cycle arrest and apoptosis in CCA cells together with the down-regulation of Bcl-2, Survivin and Cyclin B1, and the up-regulation of cleaved PARP.

In Vivo: Tanespimycin (25-200 mg/kg, i.p.) causes a dose-dependent decline in AR, HER2, and Akt expression in prostate cancer xenografts. Tanespimycin treatment at doses sufficient to induce AR, HER2, and Akt degradation results in the dose-dependent inhibition of androgen-dependent and -independent prostate cancer xenograft growth without toxicity.
Tanespimycin (60 mg/kg) with Rapamycin (30 mg/kg) inhibits A549 and MDA-MB-231 tumor growth and effects tumor cures in MDA-MB-231 tumor-bearing animals by tail vein injection.

相关产品：Covalent Screening Library Plus  |  Drug Repurposing Compound Library Plus  |  Clinical Compound Library Plus  |  Bioactive Compound Library Plus  |  Anti-Infection Compound Library  |  Apoptosis Compound Library  |  Cell Cycle/DNA Damage Compound Library  |  Kinase Inhibitor Library  |  Metabolism/Protease Compound Library  |  Anti-Cancer Compound Library  |  Clinical Compound Library  |  Autophagy Compound Library  |  Anti-Aging Compound Library  |  Drug Repurposing Compound Library  |  Covalent Screening Library  |  Antibacterial Compound Library  |  Endoplasmic Reticulum Stress Compound Library  |  Pyroptosis Compound Library  |  Cytoskeleton Compound Library  |  Antibiotics Library  |  Anti-Breast Cancer Compound Library  |  Mitochondria-Targeted Compound Library  |  Rare Diseases Drug Library  |  MG-132  |  Rapamycin  |  3-Methyladenine  |  LY294002  |  Doxorubicin hydrochloride  |  Chloroquine  |  Bafilomycin A1  |  Olaparib  |  Y-27632 dihydrochloride  |  Paclitaxel  |  Puromycin dihydrochloride  |  Acetylcysteine  |  Dexamethasone  |  Angiotensin II human  |  Deferoxamine mesylate  |  Tamoxifen  |  Adezmapimod  |  Cycloheximide  |  Staurosporine  |  2-Deoxy-D-glucose  |  Bortezomib  |  5-Fluorouracil  |  Sorafenib  |  SP600125  |  Trametinib  |  G-418 disulfate  |  Temozolomide  |  Gemcitabine  |  MK-2206 dihydrochloride

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  染料试剂  |  PROTAC  |  同位素标记物  |  寡核苷酸

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种TOP期刊及制药专利收录了MCE客户的科研成果；
•   专业团队跟踪前沿的制药及生命科学研究进展，为您提供全球前沿的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。